Eli Lilly and Company (NYSE:LLY) Shares Purchased by Cullinan Associates Inc.

Cullinan Associates Inc. lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,366 shares of the company’s stock after purchasing an additional 83 shares during the quarter. Cullinan Associates Inc.’s holdings in Eli Lilly and Company were worth $8,503,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in LLY. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $36,000. Redmont Wealth Advisors LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Morton Brown Family Wealth LLC increased its stake in Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC increased its stake in Eli Lilly and Company by 53.3% in the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after purchasing an additional 16 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $892.51 on Friday. The firm has a market capitalization of $848.27 billion, a PE ratio of 109.92, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The stock has a 50 day moving average of $920.32 and a 200-day moving average of $860.96. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 14.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target for the company. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Citigroup lifted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday. Finally, Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.